The State of China Biotech - Part II
Facts and Figures from ChinaBio -
Technology Development and Clinical Trial Activity
on February 17, 2009
There has been much debate on the state of new drug development in China. Are there novel molecules being discovered there? What is the level of clinical trial activity? Are VCs investing in China? What about M&A and IPOs?
Greg Scott, President of ChinaBio, presents research data for 2008 for the first time, at an executive workshop held at Wilson Sonsini Goodrich & Rosati in San Francisco during the JP Morgan 27th Annual Healthcare Conference.
This segment focuses on technology development as manifested by patent trends - analyzed by indication, sources and location; and on clinical trial activity and current status.
Tags: China, ChinaBio, Greg Scott, China biotech, clinical trial